These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8035403)

  • 1. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes.
    Guzmán J; Petty RE; Malleson PN
    J Rheumatol; 1994 Apr; 21(4):739-43. PubMed ID: 8035403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. von Willebrand factor in juvenile dermatomyositis.
    Bloom BJ; Tucker LB; Miller LC; Schaller JG
    J Rheumatol; 1995 Feb; 22(2):320-5. PubMed ID: 7738956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle MRI at the time of questionable disease flares in Juvenile Dermatomyositis (JDM).
    Abdul-Aziz R; Yu CY; Adler B; Bout-Tabaku S; Lintner KE; Moore-Clingenpeel M; Spencer CH
    Pediatr Rheumatol Online J; 2017 Apr; 15(1):25. PubMed ID: 28403889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of illness is an important variable for untreated children with juvenile dermatomyositis.
    Pachman LM; Abbott K; Sinacore JM; Amoruso L; Dyer A; Lipton R; Ilowite N; Hom C; Cawkwell G; White A; Rivas-Chacon R; Kimura Y; Ray L; Ramsey-Goldman R
    J Pediatr; 2006 Feb; 148(2):247-53. PubMed ID: 16492437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
    Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
    Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum muscle enzymes, muscle pathology and clinical muscle weakness: correlation in Thai patients with polymyositis/dermatomyositis.
    Louthrenoo W; Weerayutwattana N; Lertprasertsuke N; Sukitawut W
    J Med Assoc Thai; 2002 Jan; 85(1):26-32. PubMed ID: 12075717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops.
    Smith RL; Sundberg J; Shamiyah E; Dyer A; Pachman LM
    J Rheumatol; 2004 Aug; 31(8):1644-9. PubMed ID: 15290747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intravenous cyclophosphamide pulse therapy for refractory juvenile dermatomyositis].
    Nakashima S; Mori M; Miyamae T; Ito S; Ibe M; Aihara Y; Yokota S
    Ryumachi; 2002 Dec; 42(6):895-902. PubMed ID: 12632609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of von Willebrand factor in patients with adult dermatomyositis.
    Komiya T; Negoro N; Kondo K; Miura K; Hirota Y; Yoshikawa J
    Clin Rheumatol; 2005 Aug; 24(4):352-7. PubMed ID: 15565394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
    Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
    Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme elevation in patients with juvenile dermatomyositis and steroid myopathy.
    Naim MY; Reed AM
    J Rheumatol; 2006 Jul; 33(7):1392-4. PubMed ID: 16821273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis.
    Maillard SM; Jones R; Owens C; Pilkington C; Woo P; Wedderburn LR; Murray KJ
    Rheumatology (Oxford); 2004 May; 43(5):603-8. PubMed ID: 14983103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores.
    McCann LJ; Garay SM; Ryan MM; Harris R; Riley P; Pilkington CA
    Rheumatology (Oxford); 2007 Aug; 46(8):1363-6. PubMed ID: 17569746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality.
    Catto AJ; Carter AM; Barrett JH; Bamford J; Rice PJ; Grant PJ
    Thromb Haemost; 1997 Jun; 77(6):1104-8. PubMed ID: 9241740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease.
    de Romeuf C; Mazurier C
    Thromb Haemost; 1998 Jul; 80(1):37-41. PubMed ID: 9684782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of enzymes in serum and cerebrospinal fluid in cases of stroke.
    Parakh N; Gupta HL; Jain A
    Neurol India; 2002 Dec; 50(4):518-9. PubMed ID: 12577113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory.
    Zhukov O; Popov J; Ramos R; Vause C; Ruden S; Sferruzza A; Dlott J; Sahud M
    Haemophilia; 2009 May; 15(3):788-96. PubMed ID: 19298374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome.
    van Genderen PJ; Boertjes RC; van Mourik JA
    Thromb Haemost; 1998 Sep; 80(3):495-8. PubMed ID: 9759633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.